Abstract
There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.
Publication types
-
Practice Guideline
-
Review
MeSH terms
-
Acute Coronary Syndrome / complications
-
Acute Coronary Syndrome / therapy*
-
Aged
-
Angioplasty, Balloon, Coronary / adverse effects
-
Angioplasty, Balloon, Coronary / instrumentation*
-
Anticoagulants / administration & dosage*
-
Anticoagulants / adverse effects
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy*
-
Benchmarking
-
Evidence-Based Medicine
-
Female
-
Fibrinolytic Agents / administration & dosage*
-
Fibrinolytic Agents / adverse effects
-
Hemorrhage / chemically induced
-
Humans
-
Male
-
Patient Selection
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Recurrence
-
Risk Assessment
-
Risk Factors
-
Stents*
-
Stroke / etiology
-
Stroke / prevention & control
-
Thrombosis / etiology
-
Thrombosis / prevention & control
-
Treatment Outcome
-
Vitamin K / antagonists & inhibitors
Substances
-
Anticoagulants
-
Fibrinolytic Agents
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Vitamin K